Manufacturing Towards A Global Scale: Invetech at the World Stem Cells & Regenerative Medicine Congress 2012
13 May 2012
Automated processing is essential to commercial success but when is the right time to invest?
David James, Invetech Director, will present at the 2012 World Stem Cells & Regenerative Medicine Congress in London. David, in conjunction with industry leaders including Timothy Mayleben, CEO, President & Director of Aastrom Biosciences and Greg Bonfiglio, Managing Partner of Proteus Venture Capital, will discuss the need for automated processing in achieving commercial success and identifying the right time to make the investment.
The session will provide attendees with valuable insights into how to commercialize cell therapies for global markets, including:
- Process Integrity - what it is and why it is important,
- Understanding the "real" cost of goods and what is required to achieve commercial targets,
- Recognizing when to change a process technology and introduce it into the clinical trials program,
- The pros & cons of customised systems versus off-the shelf instruments,
- Identifying whether a process is truly "scalable", and if the equipment, people and systems are in place to succeed, and
- Deciding the right time to invest in automation knowing clinical trials are expensive, and the outcome is uncertain.
Join us to learn more about how to build the bridge from development to commercialization.
World Stem Cells & Regenerative Medicine Congress 2012
21-23 May 2012
Victoria Park Plaza
The need for foresight – automated processing is essential to commercial success but when is the right time to invest?
When: Day Two, Tuesday 22 May at 3pm
Stream A: Cell Therapy & Regenerative Medicine
For more information visit the World Stem Cells & Regenerative Medicine Congress website.
Further Press Information
Alan Morris, Phone: +613 9211 7815, Fax: +613 9211 7703. Media Inquiries.